The World Health Organization recommended increased dosages of the first-line antituberculosis (anti-TB) drugs for children in 2010. We examined the frequency of and factors associated with low plasma maximum concentration (C max ) of each drug in children treated with the revised dosages. Methods: Children on anti-TB therapy for at least 4 weeks underwent pharmacokinetic testing. Plasma C max below the lower limit of proposed reference range was considered low. Bivariate and multivariate analyses were used to examine the factors associated with low C max of each drug. Results: Of the 100 children, 58% were male, 50% HIV-infected and 49% younger than 5 years old. The median (interquartile range) C max was 5.9 (4.5-7.7) µg/mL for isoniazid, 6.5 (4.9-8.8) µg/mL for rifampin, 26.0 (21.2-33.4) µg/mL for pyrazinamide and 1.7 (0.9-2.7) µg/mL for ethambutol. There was a strong correlation between C max and AUC 0-8h for all drugs. Low C max occurred in 9/100 (9.0%), 61/100 (61.0%), 17/97 (17.5%) and 60/97 (61.9%) for isoniazid, rifampin, pyrazinamide and ethambutol, respectively. In addition, 75/97 (77.3%) children had pyrazinamide C max < 35 µg/mL. Factors associated with low C max were NAT2 metabolizer phenotype status for isoniazid; height, dosage and HIV coinfection status for rifampin; height for pyrazinamide; and age, dosage and HIV coinfection status for ethambutol.
A ppropriate dosing of the antituberculosis (anti-TB) drugs in children is a significant problem in optimizing tuberculosis (TB) treatment outcomes. In the absence of direct pediatric pharmacokinetic-pharmacodynamic data, it is expected that effective anti-TB drugs in adults should be effective in children provided the recommended dosages lead to pharmacokinetic profile associated with efficacy and safety. 1, 2 In vitro and animal studies suggest that antimycobacterial killing and prevention of acquired drug resistance of the first-line drugs is dependent on the area under the time curve to minimal inhibitory concentration (AUC/MIC) ratio or maximum concentration to MIC (C max /MIC) ratio. [3] [4] [5] [6] A number of clinical studies in adults have also shown that early bactericidal activity (EBA) is dependent on drug dosage or C max for isoniazid 7, 8 and dosage of rifampin or rifapentine. 9 In addition, 2 recent studies showed that, in humans, higher rifampicin dosage or exposure leads to better outcomes. 10, 11 In practice, normal ranges of 2-hour postdose serum concentration (C 2-h) of the first-line anti-TB drugs (an approximate surrogate for C max ) in adults have been widely used for therapeutic drug monitoring, with C 2-h below the lower limit of the reference range of each drug considered to be low. 12 Previous dosing of the first-line anti-TB drugs in children using similar dosages in mg/kg as in adults led to a large proportion of children with low C max . [13] [14] [15] [16] [17] [18] With the concern that low C 2-h or C max of the anti-TB drugs was associated with poor treatment outcomes, the World Health Organization (WHO) recommended increased dosages of all first-line anti-TB drugs in children in 2010. 19 As the WHO recommendations were not based on direct pharmacokinetic data, it is essential to examine the adequacy of the revised dosages in pharmacokinetic and safety studies in children.
Pharmacokinetic studies that have examined the adequacy of the revised dosages in children to date have reported conflicting findings. One study found that the revised dosages achieved target plasma C max of isoniazid, rifampin and pyrazinamide in a vast majority of South African children < 2 years of age. 20 However, subsequent studies, 1 among 31 children ≤ 10 years of age found that 94%, 85% and 45% of the children had subtherapeutic C 2-h of rifampin, ethambutol and pyrazinamide respectively, 21 while the other in infants younger than 12 months old reported that none of the participants achieved target rifampin C max , and only 1 of the 16 infants (6%) achieved target ethambutol C max . 22 In a preliminary study of the revised dosages in Ghanaian children, we found that most children achieved the target plasma C max of isoniazid and pyrazinamide but 52% and 59% of participants who received revised dosages had low C max for ethambutol and rifampin, respectively. 23 The current analysis, which included patients in our previous publication is the largest study to date (to the best of our knowledge) to examine the frequency low C max of the 4 first-line anti-TB drugs in children treated according to the current WHO guidelines. In addition, we investigated the factors associated with low C max of each of drug.
MATERIALS AND METHODS

Study Population and Design
Children 3 months to 14 years of age with clinical diagnosis of active TB were enrolled at Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana between October 2012 and August 2015. Active TB was defined as the presence of clinical symptoms, signs, radiographic findings that are consistent with active TB, with or without positive acid-fast bacilli in sputum or tissue samples. In addition, lymph node biopsy sample showing granuloma with or without a positive acid-fast bacilli was considered as active TB. No Mycobacterial cultures were available at the study site or were done in this study. Eligible children were excluded if their parents refused to participate or could not return for scheduled study visits or did not receive the revised weight-band dosages. The Institutional Review Board of KATH, Ghana and Lifespan Hospitals, Providence, Rhode Island, reviewed and approved the study. All parents or guardians of the study participants provided signed informed consent. The study was registered with ClinicalTrials.gov, number NCT01687504.
Study Procedures
All participants were given a regimen consisting of isoniazid (7-15 mg/kg), rifampin (10-20 mg/kg), pyrazinamide (30-40 mg/kg) and ethambutol (15-25 mg/kg) daily for 2 months then isoniazid and rifampin daily for 4 months. The medications were dosed according to WHO guidelines for using available dispersible fixed-dose combination (FDC) tablets for children in the weight bands 5-7 kg, 8-14 kg, 15-20 kg, 21-30 kg, 31-39 kg and 40-54 kg. 24 The FDC tablets containing rifampin 60 mg, isoniazid 30 mg and pyrazinamide 150 mg; rifampin 60 mg and isoniazid 30 mg; and rifampin 60 mg and isoniazid 60 mg were used. Ethambutol 100 mg tablets were used. The isoniazid/rifampin/ pyrazinamide dispersible FDC tablets given to children with body weight < 21 kg were manufactured by MaCleods Pharmaceuticals, Mumbai, India, and the ethambutol tablets by Riemser Pharma GmbH, Schiffweiler, Germany. Isoniazid/rifampin/pyrazinamide/ethambutol FDC tablets given to children with body weight ≥ 21 kg were manufactured by Lupin Ltd, Chkalthana, Aurangabad, India. All the medications were supplied through the WHO Global TB Drug Facility and were dosed according to WHO guidelines for using available dispersible FDC TB medicines for children. 24 Given the ratio of pyrazinamide in the FDC tablet, it was not possible to achieve the revised dosage range in all children. The medications were either swallowed or dispersed in water in a plastic cup. Ingestion of medications after an overnight fast was observed by a health-care worker during hospitalization and by a family member at home.
Pharmacokinetic sampling was performed after at least 4 weeks of anti-TB treatment as previously described. 23 Blood samples were collected at times 0 (predose), 1, 2, 4 and 8-hours after observed dosing in the hospital. The samples collected in ethylenediaminetetraacetic acid (EDTA)-coated tubes were placed immediately on ice and centrifuged within 30 minutes at 3000 g for 10 minutes. Plasma was stored at ˗80 o C until shipment on dry ice to University of Cape Town, Cape Town, South Africa for drug concentrations assays.
Pharmacokinetic Analysis
Drug concentrations were determined using validated liquid chromatography tandem with mass spectrometry methods as we previously described. 23 The observed C max and time to C max (T max ) were determined by inspection of the serum concentration-time graphs for each drug and AUC from time 0 to 8 hours (AUC 0-8h ) was calculated using noncompartmental analysis (Phoenix Software; Pharsight Corporation, Mountain View, CA). The observed C max of each drug below the proposed lower limit of the following reference ranges in adults were considered to be low: isoniazid 3-6 µg/mL, rifampin 8-24 µg/mL and pyrazinamide 20-50 µg/ mL and ethambutol 2-6 µg/mL.
12 Pyrazinamide plasma C max < 35 µg/mL was considered as low in secondary analysis as that cutoff was associated with poor treatment outcome in 1 study in predominantly HIV-infected adults in Botswana.
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N-acetyltransferase-2 (NAT2) Genotyping
Genotyping for N-acetyltransferase type 2 (NAT2) single nucleotide polymorphisms (SNPs) rs1801279 (191G→A), rs1801280 (341T→C), rs1799930 (590G→A) and rs1799931 (857G→A) was performed using validated TaqMan® real-time polymerase chain reaction (PCR) assays. Samples homozygous wild-type for all SNPs were classified as rapid, those heterozygous for any one of the SNPs were classified intermediate, and those homozygous variant for one or more SNPs or heterozygous for 2 or more SNPs were classified slow acetylator genotypes according established criteria.
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Sample Size Justification
The sample size calculation was based on a primary endpoint that compared drugs C max in children with TB with or without HIV coinfection as described in our previous publication. 27 We assumed that a C max coefficient of variation of 0.35-0.60 based on available literature, a sample size of 23-64 per group (or 46-128) was needed to detect a 30% or greater difference in each drug C max between the 2 groups, with the minimum power of 80%. Overall, the study enrolled 113 patients, 55 with TB alone and 59 with HIV/ TB coinfection. 27 In the current article, we excluded 13 patients who received drug dosages based on the old WHO recommendations, leaving 100 patients in the final analysis.
Statistical Analysis
Statistical analyses were performed using Software R for Windows 3.3.1 and SAS 9.4 (SAS Institute Inc, Cary, NC). Weight-for-age Z score (WAZ), height-for-age Z score (HAZ) and body mass index (BMI)-for age were calculated based on the United States National Center for Health Statistics reference median values using statistical macros for children < 5 years and 5-19 years of age provided by the WHO. 28 Bivariate analysis including Wilcoxon rank sum test and Fisher exact test was used to assess the marginal effect of demographic and clinical variables on whether C max falls in reference ranges. The joint effects of patient factors (HIV coinfection, sex, age, height, weight-adjusted dose and isoniazid-specific 4-SNP NAT2 nonslow metabolizing phenotype status) on probability of having low C max was explored by logistic regression with variable selection by the Minimax Concave Penalty method 29, 30 to improve the efficiency of inference. Given that C max is the pharmacokinetic parameter used in therapeutic drug monitoring, we examined the correlation between C max and AUC 0-8h as well with C 2-h using Pearson correlation analysis and confirmed the association by Spearman Correlation. For all analyses, a P value < 0.05 was considered significant.
RESULTS
Study Population
Of 113 children enrolled during the study period, 13 who received dosages according to previous WHO TB treatment guidelines were excluded. Of the 100 study participants who were treated according to the 2010 revised dosage guidelines, 50.0% had HIV coinfection, 58.0% were male, 49.0% < 5 years and 23.0% < 2 years of age. The median (range) dosages of the drugs given were isoniazid 11.4 (9.7-12.9) mg/kg, rifampin 16.5 (14.4-19.0) mg/kg, pyrazinamide 25.9 (22.6-30.4) mg/kg and ethambutol 17.2 (15.1-20.6) mg/kg. Overall, 86 children completed anti-TB treatment, 12 were lost to follow-up or discontinued the study and 2 died.
The median (interquartile range [IQR]) plasma C max for isoniazid was 5.9 (4.5-7.7) µg/mL, for rifampin 6.5 (4.9-8.8) µg/mL, for pyrazinamide 26.0 (21.2-33.4) µg/mL and for ethambutol 1.7 (0.9-2.7) µg/mL. The median (IQR) AUC 0-8hr for isoniazid was 21.2 (15.2-27.9) µg.hr/mL, for rifampin 27.5 (21.0-37.4) µg.hr/ mL, for pyrazinamide 134.9 (110.8-179.4) µg.hr/mL and for ethambutol 6.1 (3.8-9.6) µg.hr/mL. As shown in Figure 1 , there was strong linear correlation between plasma C max and AUC 0-8hr for all the drugs studied. There was also a strong linear correlation between plasma C max and C 2-h for all the drugs ( . Among the children that we could establish C max and C 2-h, C max was either equal to or greater than but never less than C 2-h (Table, Supplemental Digital Content 3, http://links.lww.com/INF/C758). Overall, C max was equal to C 2-h in 67% and 52%, respectively, for ethambutol and rifampin (Table, Supplemental 
Proportion of Children With Low Anti-TB Drug C max
Of the 100 children, 3 had undetectable pyrazinamide and ethambutol concentrations at all the sampling points. Overall, 9/100 (9.0%) had low isoniazid C max , 61/100 (61%) had low rifampin C max , 17/97 (17.5%) had low pyrazinamide C max and 60/97 (61.8%) had low ethambutol C max (Fig. 2) . Of the 97 children who had detectable concentrations of all the 4 first-line drugs, 42 (43.3%) had low C max of rifampin and ethambutol and 3 (3.1%) had low C max of all the drugs. If C 2-h is used as the pharmacokinetic parameter, 20/93 (21.5%) had low isoniazid C 2-h, 65/93 (69.9%) had low rifampin C 2-h, 27/91 (29.7%) had low pyrazinamide C 2-h and 59/90 (65.6%) had low ethambutol C 2-h.
Using other published thresholds, 75/97 (77.3%) of the children had pyrazinamide C max < 35 µg/mL (Fig. 2) , a cutoff that was associated with poor treatment outcome in 1 study in predominantly HIV-infected adults in Botswana. 25 Also, 81/97 (83.5%) of the children had pyrazinamide C max < 38.1 µg/mL, a recently proposed statistically derived threshold of pyrazinamide associated with treatment failure and death in Indian children with TB. 31 Of the 81 children with pyrazinamide, C max < 38.1 µg/mL, 43 (53.1%) had rifampin C max < 6.20 µg/mL, a rifampin threshold considered to be associated with poor outcome in the study in Indian children. 31 
Factors Associated With Low C max of the Four FirstLine Drugs
The factors associated with low C max of each drug were examined using bivariate (Tables 1-4 ) and multivariate analysis (Fig. 3) . For isoniazid, children with 4-SNP NAT2 nonslow (intermediate/fast) compared with those with slow metabolizing phenotype were more likely to have low isoniazid C max in the bivariate analysis (Table 1) Children with low rifampin C max compared with those with C max within the reference range were more likely to have received a lower median rifampin dose (15.5 mg/kg versus 17.6 mg/kg) or have a lower HAZ (˗2.6 versus ˗1.6; Table 2 ). In the multivariate analysis, HIV coinfection status (OR, 2.45; 95% CI, 1.01-5.95), height (OR, 0.97; 95% CI, 0.96-0.99) and rifampin dose (OR, 0.81; 95% CI, 0.68-0.95) were associated with low rifampin C max (Fig. 3B) .
For pyrazinamide, children with low C max were more likely than those with C max within the reference range to have a lower median age (1.7 versus 5.0 years old), body weight (7.5 versus 14.1 kg), or shorter height (77.0 versus 99.5 cm; Table 3 ). In the multivariate model, only height (OR, 0.96; 95% CI, 0.93-0.99) was significantly associated with low pyrazinamide C max (Fig. 3C) .
For ethambutol, children with low C max compared with those with C max in the proposed reference range were more likely to have a lower median age (4.1 versus 7.3 years old), lower body weight (12.8 versus 16.3 kg), shorter height (94.0 versus 107 cm), shorter mid-arm circumference (13.0 versus 14.3 cm), or received a lower median dosage (15.9 mg/kg versus 18.8 mg/kg; Table 4 ). In the multivariate analysis, HIV coinfection status (OR, 5.37; 95% CI, 1.87-15.37), age (OR, 0.83; 95% CI, 0.73-0.95) and ethambutol dose (OR, 0.82; 95% CI, 0.72-0.92) were associated with low C max (Fig. 3D ).
DISCUSSION
At least 1 million children develop active TB each year, with an estimated 210,000 deaths in 2015. 32 Optimizing the dosages of anti-TB drugs in children is challenging, given the lack of reliable pediatric pharmacokinetic-pharmacodynamic data to inform dosing decisions. With the implementation of WHO revised dosages of the first-line anti-TB drugs for children, pharmacokinetic studies that sought to determine whether most children achieve plasma C max within proposed reference ranges have reported conflicting findings. [20] [21] [22] [23] In the current study, we found that a majority of children in the study achieved C max of isoniazid and pyrazinamide within proposed reference ranges, 12 but at least 60% of the children had low rifampin or ethambutol C max . Our finding of a high frequency of low rifampin and ethambutol C max despite using currently recommended dosages is consistent with those of 2 other published studies from South Africa 21, 22 but differs from findings of 1 study that found the revised dosages of isoniazid, rifampin and pyrazinamide to be adequate. 20 Overall, the emerging data ( revised dosages of the first-line drugs for children failed to achieve desired plasma C max or C 2-h except for isoniazid.
In assessing the adequacy of the current WHO recommended dosages of the first-line drugs, we used proposed reference C 2-h ranges to define low drug concentrations 12, 33 as optimal pharmacokinetic parameters associated with unfavorable clinical outcomes (especially in children) are not well established. We did not have adequate variability in clinical outcomes in our study population to evaluate the relationship between the administered dosages and clinical effect. Some clinical studies have reported a significant relationship between pyrazinamide C max or C 2-h and TB treatment outcome but the thresholds have not been validated. 25, 34, 35 For isoniazid, rifampin and ethambutol, there is very limited direct data on the relationship between plasma C max and clinical outcome. For example, 1 retrospective study among adults with TB in Canada found that 2-month sputum conversion rate was associated with low isoniazid C max and a trend toward low rifampin C max 36 but prospective data are lacking.
Rifampin and pyrazinamide are critical components of current short-course chemotherapy that allowed for anti-TB treatment to be shortened from 24 to 6 months. 37 For rifampin, our finding of at least 60% with low plasma C max is concerning as low exposure to the rifamycins in particular have been associated with TB treatment failure and emergence of rifamycin resistance. [38] [39] [40] A comprehensive review of published data on the pharmacokinetics and pharmacodynamics of rifampin in adults and children that applied straight line regression of C max on dose reported that children established on rifampin require approximately twice the mg/kg body weight dosage of rifampin as in adults to reach serum concentrations equivalent to adults. 41 Thus, if adults need higher rifampin dosages to improve anti-TB treatment outcomes or shorten treatment duration, 10, 11, 42 then children will likely need higher than currently recommended dosages too. For pyrazinamide, the inability to achieve C max > 35 µg/mL in most children in our study was likely due to under dosing, as it is not possible to give the recommended dosage range using the available rifampin/isoniazid/pyrazinamide FDC tablets. Even with the newer formulation of rifampin/isoniazid/pyrazinamide 75/50/150 FDC tablet and new revised weightband dosing guidelines recommended by WHO, 43 children at the upper end of the weight-bands (except for the 12-15 kg) will be under dosed. Thus, newer FDC tablets with appropriate proportion of pyrazinamide are needed.
Low ethambutol C max was common in our study population based on the proposed reference range but whether an increase in dosage is necessary is unclear as there are no direct pharmacokinetic-pharmacodynamic data. Although ethambutol optic toxicity in adults is dose related, for severe disease in children, the upper end of the dosage range of 15-25 mg/kg could be used as toxicity in children, given a dose of 15-30 mg/kg was rare. 13 Also, if ethambutol is used in the setting of high prevalence of isoniazid resistance, in the absence of other alternatives, the higher recommended dosage of 25 mg/kg can be used with careful age-appropriate monitoring for optic toxicity as ethambutol efficacy is dosage related. 44 We investigated the factors associated low C max of each drug. In the multivariate analysis, only NAT2 metabolizing phenotype status was associated with low isoniazid C max and height was associated with low pyrazinamide C max . HIV coinfection status and drug dosage were associated with low C max of rifampin and ethambutol. In addition, height was associated with rifampin C max and age with low ethambutol C max . While we do not propose individualized dosing of the anti-TB drugs based on the above factors as it is not practical, the significant factors should be considered when pharmacologic modeling is used to determine the appropriate dosages of the drugs in children at the population level. The finding that lower dosages were associated with low C max of rifampin and ethambutol suggest that a dose increase for these drugs could improve pharmacokinetic profiles in children if deemed necessary based on clinical efficacy studies.
Another important finding of our study is that plasma C max or C 2-h was reflective of AUC 0-8h for all the 4 drugs. Thus, when AUC cannot be performed, especially in large clinical studies, C max 
